{"id":185345,"date":"2017-03-29T11:29:14","date_gmt":"2017-03-29T15:29:14","guid":{"rendered":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/the-stryker-co-syk-to-issue-quarterly-dividend-of-0-43-on-april-28th-petro-global-news-24\/"},"modified":"2017-03-29T11:29:14","modified_gmt":"2017-03-29T15:29:14","slug":"the-stryker-co-syk-to-issue-quarterly-dividend-of-0-43-on-april-28th-petro-global-news-24","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/the-stryker-co-syk-to-issue-quarterly-dividend-of-0-43-on-april-28th-petro-global-news-24\/","title":{"rendered":"The Stryker Co. (SYK) to Issue Quarterly Dividend of $0.43 on April 28th &#8211; Petro Global News 24"},"content":{"rendered":"<p><p>    Stryker Co. (NYSE:SYK) declared a quarterly dividend on    Wednesday, February 8th. Stockholders of record on Friday,    March 31st will be given a dividend of 0.425 per share by the    medical technology company on Friday, April 28th. This    represents a $1.70 dividend on an annualized basis and a    dividend yield of 1.28%. The ex-dividend date of this dividend    is Wednesday, March 29th.  <\/p>\n<p>    Stryker (NYSE:SYK) opened at 132.49 on Tuesday. The stock has a    50 day moving average price of $128.69 and a 200-day moving    average price of $119.60. Stryker has a 1-year low of $104.61    and a 1-year high of $133.59. The stock has a market    capitalization of $49.40 billion, a P\/E ratio of 30.46 and a    beta of 0.80.  <\/p>\n<p>    Stryker (NYSE:SYK) last issued its quarterly earnings data on    Tuesday, January 24th. The medical technology company reported    $1.78 EPS for the quarter, topping analysts consensus    estimates of $1.76 by $0.02. The company earned $3.20 billion    during the quarter, compared to the consensus estimate of $3.15    billion. Stryker had a net margin of 14.54% and a return on    equity of 23.86%. Strykers revenue for the quarter was up    16.3% compared to the same quarter last year. During the same    quarter in the previous year, the firm posted $1.56 earnings    per share. Equities research analysts expect that Stryker will    post $6.41 EPS for the current year.  <\/p>\n<p>    SYK has been the subject of a number of recent research    reports. Needham & Company LLC reissued a sell rating on    shares of Stryker in a research note on Wednesday, January    25th. Wells Fargo & Co reissued an outperform rating and    issued a $134.50 price objective on shares of Stryker in a    research note on Saturday, January 28th. Jefferies Group LLC    boosted their price objective on shares of Stryker from $120.00    to $132.00 and gave the stock a hold rating in a research    note on Wednesday, January 25th. Edward Jones downgraded shares    of Stryker from a buy rating to a hold rating in a research    note on Thursday, January 5th. Finally, Zacks Investment    Research raised shares of Stryker from a hold rating to a    buy rating and set a $125.00 price objective for the company    in a research note on Monday, December 5th. Two analysts have    rated the stock with a sell rating, seven have given a hold    rating and thirteen have issued a buy rating to the companys    stock. Stryker has a consensus rating of Buy and an average    target price of $127.74.  <\/p>\n<p>    In related news, VP Yin C. Becker sold 4,398 shares of the    companys stock in a transaction dated Wednesday, February    15th. The shares were sold at an average price of $125.27, for    a total transaction of $550,937.46. Following the completion of    the transaction, the vice president now owns 12,541 shares in    the company, valued at approximately $1,571,011.07. The    transaction was disclosed in a legal filing with the SEC, which    can be accessed through the SEC website. Also, Director Louise    Francesconi sold 3,716 shares of the companys stock in a    transaction dated Monday, January 30th. The stock was sold at    an average price of $122.34, for a total transaction of    $454,615.44. Following the transaction, the director now owns    20,242 shares of the companys stock, valued at approximately    $2,476,406.28. The disclosure for this sale can be found here.    Over the last three months, insiders have sold 24,968 shares of    company stock worth $3,033,715. Corporate insiders own 7.80% of    the companys stock.  <\/p>\n<p>    About Stryker  <\/p>\n<p>    Stryker Corporation is a medical technology company. The    Company offers a range of medical technologies, including    orthopedic, medical and surgical, and neurotechnology and spine    products. The Companys segments include Orthopaedics; MedSurg;    Neurotechnology and Spine, and Corporate and Other. The    Orthopaedics segment includes reconstructive (hip and knee) and    trauma implant systems and other related products.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Go here to read the rest: <\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"http:\/\/petroglobalnews24.com\/2017-03-29-stryker-co-syk-to-issue-quarterly-dividend-of-0-43-on-april-28th\/\" title=\"The Stryker Co. (SYK) to Issue Quarterly Dividend of $0.43 on April 28th - Petro Global News 24\">The Stryker Co. (SYK) to Issue Quarterly Dividend of $0.43 on April 28th - Petro Global News 24<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Stryker Co. (NYSE:SYK) declared a quarterly dividend on Wednesday, February 8th.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/the-stryker-co-syk-to-issue-quarterly-dividend-of-0-43-on-april-28th-petro-global-news-24\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187755],"tags":[],"class_list":["post-185345","post","type-post","status-publish","format-standard","hentry","category-neurotechnology"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/185345"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=185345"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/185345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=185345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=185345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=185345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}